iBio, Inc. Share Price & Technical Analysis
IBIO · $1.84 (-2.65%)
Healthcare / Biotechnology
$1.84
-2.65%
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
13% return in May, -4% avg return in past 3 year May month.
13% return in 2026, 98% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 5% | 33% | -27% | -11% | 13% | – | – | – | – | – | – | – | 13% |
| 25 | 20% | 100% | -30% | -72% | -20% | 0% | -12% | 14% | 0% | 100% | -25% | 58% | 133% |
| 24 | -21% | 18% | 242% | -53% | 41% | -16% | -5% | -5% | 10% | 18% | 12% | -14% | 227% |
| 23 | 59% | 73% | 60% | -49% | -34% | -13% | -18% | -40% | 0% | -16% | -39% | -50% | -67% |
| 22 | -13% | -35% | 34% | -33% | -20% | 8% | -12% | 22% | -39% | -48% | -29% | -72% | -237% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and MUC16 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells; and TROP-2 x CD3 bispecific antibody that is developed with EngageTx platform to harness T cells to kill TROP-2expressing tumors while minimizing the cytokine release that often limits the tolerability of T-cell engagers. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. The company was formerly known as iBioPharma, Inc. and changed its name to iBio, Inc. in August 2009. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$57.47M
P/E ratio
—
52W high
$3.82
52W low
$0.56
Volume
6,00,814
Beta
1.24
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is iBio, Inc. share price today?
- iBio, Inc. (IBIO) last traded around $1.84 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does IBIO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for IBIO. Download the app for real-time alerts.
- How can I analyze iBio, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.